Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
 at Neurocritical Care Society 2016 Annual Meeting - EconoTimes)
SOUTH SAN FRANCISCO, Calif., Sept. 13, 2016 -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today announced that Phase 3 clinical data and preclinical data from studies of the Company’s Factor Xa inhibitor antidote AndexXaTM (andexanet alfa) will be presented in poster sessions at the upcoming 14th Annual Neurocritical Care Society Meeting, which will take place from September 15-18 in National Harbor, Md. Additionally, results of a retrospective chart review on treatment patterns and outcomes of patients receiving oral Factor Xa inhibitors who experienced life-threatening intracranial hemorrhage (ICH) will be presented in a poster session.
AndexXa, a U.S. Food and Drug Administration (FDA)-designated Breakthrough Therapy, is in development for patients treated with a direct (apixaban, rivaroxaban, or edoxaban) or indirect (enoxaparin) Factor Xa inhibitor when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding. Currently, there is no FDA-approved antidote to reverse the anticoagulant activity of Factor X inhibitors. Portola is committed to conducting and supporting research to understand the real-world management, outcomes and resource utilization of Factor Xa inhibitor-associated major bleeding in order to improve morbidity and mortality in these patients.
The abstracts are now available at http://www.neurocriticalcare.org/Meetings/2016-Annual-Meeting/2016-Abstract-Submission-and-Poster-Information. Following are details of the poster presentations, which will take place in Prince George Exhibit Hall A of the Gaylord National Resort and Convention Center. The posters will include additional data not available in the posted abstracts.
AndexXa Poster Presentations
- Abstract Title: The effect of andexanet alfa on the pharmacokinetics and renal clearance of the direct Factor Xa inhibitors
Abstract Poster Number: 128
Presenting Author: Janet M. Leeds, Ph.D., senior director, Drug Metabolism and Pharmacokinetics, Portola Pharmaceuticals
Presentation Date and Time: Friday, September 16, 5:30-6:30 p.m. EDT
- Abstract Title: Andexanet alfa but not prothrombin complex concentrate reverses rivaroxaban-induced anticoagulation and reduces blood loss in a rabbit liver laceration model
Abstract Poster Number: 8
Presenting Author: Polly Pine, Ph.D., head of pharmacology, Portola Pharmaceuticals
Presentation Date and Time: Friday, September 16, 5:30-6:30 p.m. EDT
- Abstract Title: Andexanet alfa, an investigational universal antidote for reversal of anticoagulation of Factor Xa inhibitors
Abstract Poster Number: 135
Presenting Author: Janet M. Leeds, Ph.D., senior director, Drug Metabolism and Pharmacokinetics, Portola Pharmaceuticals
Presentation Date and Time: Saturday, September 17, 5:30-6:30 p.m. EDT
Retrospective Chart Review Poster Presentation
- Abstract Title: Treatment patterns and outcomes of patients receiving oral Factor Xa inhibitors or low molecular weight heparin who experienced life-threatening intracranial hemorrhage: A retrospective chart review
Abstract Poster Number: 78
Presenting Author: W. Richey Neuman, M.D., M.P.H., vice president, Medical Affairs, Portola Pharmaceuticals
Presentation Date and Time: Friday, September 16, 5:30-6:30 p.m. EDT
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company is advancing three programs, including betrixaban, an oral, once-daily Factor Xa inhibitor; AndexXa™ (andexanet alfa), a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a Syk/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective Syk inhibitors for inflammatory conditions. For more information, visit www.portola.com and follow the Company on Twitter @Portola_Pharma.
Investor Contact: Ana Kapor Portola Pharmaceuticals [email protected] Media Contact: Julie Normart W2O Group [email protected] 415.946.1087
